Philip Hampton, GSK
GSK announced that its non-executive chairman, Philip Hampton, would step down from his position. Ahead of the merger of Pfizer and GSK’s healthcare companies, which will see GSK split up its business into a pure pharmaceutical company and a separate consumer healthcare business.
Hampton has held the role of chairman for three and a half years after joining the board on January 1, 2015. Before GSK, he held the position of chairman at RBS and J Sainsbury.
“GSK has made very good progress with a new strategy and new approach to R&D. Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new chair to oversee this process through to its conclusion over the next few years and to lead the board into this next phase for GSK,” said Hampton.
GSK announced that it will begin the process of finding a successor immediately.